MarketCapExport financials
Teva Pharmaceutical Industries Limited (TEVA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Teva Pharmaceutical Industries Limited Income Statement 2025-2006 | TEVA
Brief overview of income trends at Teva Pharmaceutical Industries Limited
The comparison covers a five-year financial horizon. Revenue at Teva Pharmaceutical Industries Limited moved from $16.7 billion in 2020 to $1.5 billion in 2025. The cumulative result was −91%, corresponding to roughly −38.2% per year. The business finished the period with a smaller revenue base.
At the gross-profit level, the result moved from $7.7 billion to $8.9 billion, a change of +15.7%. The relationship between sales and direct costs deteriorated. Gross margin moved from 46.4% to 595.9%. The margin shift points to a more favorable sales-and-cost structure.
Over the period, EBITDA shifted from −$2 billion to $3.2 billion, a change of +256.8%. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin moved from −12.1% to 210.6%. A wider margin confirms stronger operating efficiency.
Across the five years, the net result shifted from −$4 billion to $1.4 billion. The return to profit marks a meaningful recovery in the final result.
Market value was $12.9 billion at the start and $41.3 billion at the end. Valuation expanded much faster than the underlying results.
Financial takeaway
The five-year picture requires weighing both strengths and weaknesses. The strongest signals are improving net profitability, a stronger gross margin and positive operating leverage. Caution is warranted because of weak sales momentum. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Teva Pharmaceutical Industries Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
41.3 B | 19.5 B | 14.5 B | 11.4 B | 9.29 B | 12.9 B | 11.2 B | 20.4 B | 21 B | 31.9 B | 49.4 B | 44.6 B | 34.7 B | 28.3 B | 33.8 B | 48.1 B | 40.6 B | 35.3 B | 30.3 B | - |
Shares |
1.14 B | 1.13 B | 1.12 B | 1.11 B | 1.1 B | 1.1 B | 1.09 B | 1.02 B | 1.02 B | 955 M | 855 M | 853 M | 849 M | 872 M | 890 M | 896 M | 872 M | 780 M | 768 M | - |
Historical Prices |
36.1 | 17.3 | 13 | 10.3 | 8.43 | 11.8 | 10.4 | 19.9 | 20.3 | 32 | 57.5 | 52 | 39.6 | 32.7 | 38 | 53.7 | 46.6 | 45.3 | 39.5 | 37.3 |
Net Income |
1.41 B | -1.64 B | -559 M | -2.45 B | 417 M | -3.99 B | -999 M | -2.15 B | -16.3 B | 329 M | 1.59 B | 3.06 B | 1.27 B | 1.96 B | 2.76 B | 3.33 B | 2 B | 609 M | 1.91 B | - |
Revenue |
1.5 B | 16.5 B | 15.8 B | 14.9 B | 15.9 B | 16.7 B | 16.9 B | 18.9 B | 22.4 B | 21.9 B | 19.7 B | 20.3 B | 20.3 B | 20.3 B | 18.3 B | - | - | - | - | - |
Cost of Revenue |
8.32 B | 8.48 B | 8.2 B | 7.95 B | 8.28 B | 8.93 B | 9.35 B | 9.98 B | 11.2 B | 10.2 B | 8.3 B | 9.22 B | 9.61 B | 9.66 B | 8.8 B | 7.06 B | 6.53 B | 5.12 B | 4.53 B | - |
Gross Profit |
8.94 B | 8.06 B | 7.64 B | 6.97 B | 7.59 B | 7.73 B | 7.54 B | 8.3 B | 10.8 B | 11.9 B | 11.4 B | 11.1 B | 10.7 B | 10.7 B | 9.52 B | 9.06 B | 7.37 B | 5.97 B | 4.88 B | - |
Operating Income |
2.16 B | -303 M | 433 M | -2.2 B | 1.72 B | -3.57 B | -443 M | -1.64 B | -17.5 B | 2.15 B | 3.35 B | 3.95 B | 1.65 B | 2.2 B | 3.11 B | 3.87 B | 2.4 B | 1.14 B | 2.4 B | - |
Interest Expense |
916 M | 1 B | 1.03 B | 930 M | 891 M | 901 M | 822 M | 920 M | 875 M | 546 M | 270 M | 300 M | 314 M | 355 M | 234 M | 202 M | 230 M | 201 M | - | - |
EBITDA |
3.16 B | 756 M | 1.59 B | -889 M | 3.05 B | -2.02 B | 1.28 B | 205 M | 6.1 B | 6.18 B | 6.42 B | 6 B | 5.6 B | 5.89 B | 5.08 B | 4.85 B | 3.31 B | 1.64 B | 2.89 B | - |
Operating Expenses |
6.78 B | 8.37 B | 7.21 B | 9.17 B | 5.88 B | 11.3 B | 4.79 B | 5.41 B | 6.83 B | 7.21 B | 6.24 B | 6.57 B | 6.75 B | 6.47 B | 5.5 B | 5.19 B | 4.96 B | 4.82 B | 2.48 B | - |
General and Administrative Expenses |
1.29 B | 1.16 B | 1.16 B | 1.18 B | 1.1 B | 1.17 B | 1.19 B | 1.3 B | 1.33 B | 1.24 B | 1.24 B | 1.22 B | 1.24 B | 1.24 B | 932 M | 865 M | 823 M | 669 M | 637 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Teva Pharmaceutical Industries Limited
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | 2009-Q1 | 2008-Q4 | 2007-Q4 | 2006-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.17 B | 1.16 B | 1.16 B | 1 B | 1.15 B | 1.15 B | 1.14 B | 1 B | 1.13 B | 1.13 B | 1.12 B | - | 1.12 B | 1.12 B | 1.12 B | 1 B | 1.11 B | 1.11 B | 1.11 B | - | 1.1 B | 1.1 B | 1.1 B | - | 1.1 B | 1.1 B | 1.09 B | - | 1.09 B | 1.09 B | 1.09 B | 3 M | 1.02 B | 1.02 B | 1.02 B | - | 1.02 B | 1.02 B | 1.02 B | -935 M | 979 M | 914 M | 913 M | 4 M | 851 M | 849 M | 851 M | 1 B | 855 M | 852 M | 850 M | -1 M | 845 M | 849 M | 855 M | -1 M | 869 M | 871 M | 880 M | -2 M | 888 M | 892 M | 897 M | 1 B | 899 M | 895 M | 892 M | 5 M | 884 M | 860 M | 857 M | 780 M | 768 M | - |
Net Income |
233 M | -575 M | 369 M | 482 M | 433 M | 283 M | 220 M | -275 M | -390 M | -874 M | -419 M | 467 M | 77 M | -906 M | -253 M | -1.33 B | 63 M | -278 M | -952 M | -152 M | 302 M | 221 M | 84 M | 150 M | -4.35 B | 140 M | 69 M | 110 M | -314 M | -689 M | -105 M | -2.94 B | -273 M | -241 M | 1.06 B | -11.6 B | 530 M | -6.04 B | 580 M | -1.04 B | 348 M | 188 M | 570 M | 485 M | 103 M | 539 M | 446 M | 707 M | 863 M | 745 M | 740 M | 393 M | 706 M | -456 M | 626 M | 280 M | -84 M | 859 M | 855 M | 505 M | 918 M | 580 M | 765 M | 773 M | 1.05 B | 800 M | 714 M | 380 M | 650 M | 523 M | 451 M | 609 M | 1.91 B | - |
Revenue |
4.4 B | 4.14 B | 3.98 B | 1.5 B | 4.48 B | 4.18 B | 3.89 B | 4.23 B | 4.33 B | 4.16 B | 3.82 B | 4.46 B | 3.85 B | 3.88 B | 3.66 B | 3.88 B | 3.6 B | 3.79 B | 3.66 B | 4.1 B | 3.89 B | 3.91 B | 3.98 B | 4.45 B | 3.98 B | 3.87 B | 4.36 B | 4.47 B | 4.09 B | 4.18 B | 4.15 B | 4.42 B | 4.38 B | 4.7 B | 4.92 B | 5.4 B | 5.62 B | 5.72 B | 5.65 B | 6.49 B | 5.56 B | 5.04 B | 4.81 B | - | 4.82 B | 4.97 B | 4.98 B | - | 5.06 B | 5.04 B | 5 B | - | 5.06 B | 4.92 B | 4.9 B | - | 4.97 B | 4.99 B | 4.99 B | - | 4.34 B | 4.21 B | 4.08 B | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
1.96 B | 1.99 B | 2.01 B | 2.06 B | 2.18 B | 2.07 B | 2.01 B | 2.11 B | 2.18 B | 2.14 B | 2.05 B | 2.04 B | 2 B | 2.08 B | 2.08 B | 2.11 B | 1.93 B | 1.99 B | 1.92 B | 2.05 B | 2.09 B | 2.04 B | 2.1 B | 2.4 B | 2.13 B | 2.11 B | 2.29 B | 2.51 B | 2.26 B | 2.28 B | 2.29 B | 2 B | 2.55 B | 2.67 B | 2.75 B | 2.59 B | 2.97 B | 2.86 B | 2.81 B | 3.31 B | 2.76 B | 2.16 B | 2.02 B | 2.03 B | 2.05 B | 2.06 B | 2.15 B | 2.28 B | 2.25 B | 2.38 B | 2.3 B | 2.54 B | 2.43 B | 2.33 B | 2.31 B | 2.46 B | 2.37 B | 2.34 B | 2.49 B | 2.8 B | 2.1 B | 2.01 B | 1.89 B | 1.95 B | 1.78 B | 1.68 B | 1.64 B | 1.7 B | 1.62 B | 1.63 B | 1.58 B | 5.12 B | 4.53 B | - |
Gross Profit |
2.44 B | 2.15 B | 1.97 B | 2.66 B | 2.3 B | 2.1 B | 1.88 B | 2.12 B | 2.15 B | 2.02 B | 1.77 B | 2.42 B | 1.85 B | 1.8 B | 1.58 B | 1.77 B | 1.67 B | 1.79 B | 1.74 B | 2.05 B | 1.79 B | 1.87 B | 1.88 B | 2.05 B | 1.85 B | 1.76 B | 2.06 B | 1.96 B | 1.83 B | 1.89 B | 1.86 B | 1.97 B | 1.98 B | 2.03 B | 2.32 B | 2.44 B | 2.6 B | 2.8 B | 2.77 B | 3.39 B | 2.8 B | 2.88 B | 2.79 B | 2.85 B | 2.77 B | 2.9 B | 2.84 B | 2.89 B | 2.81 B | 2.66 B | 2.7 B | 2.89 B | 2.63 B | 2.59 B | 2.59 B | 2.78 B | 2.6 B | 2.66 B | 2.61 B | 2.88 B | 2.25 B | 2.2 B | 2.19 B | 2.46 B | 2.47 B | 2.12 B | 2.01 B | 2.1 B | 1.93 B | 1.77 B | 1.57 B | 5.97 B | 4.88 B | - |
Operating Income |
714 M | -231 M | 652 M | 300 M | 882 M | 455 M | 519 M | -29 M | -51 M | -5 M | -218 M | 756 M | 344 M | -654 M | -13 M | -940 M | 424 M | -967 M | -713 M | 78 M | 623 M | 582 M | 434 M | 406 M | -4.34 B | 173 M | 191 M | 148 M | -81 M | -644 M | 134 M | -3.16 B | 16 M | -14 M | 1.52 B | -13 B | 378 M | -5.74 B | 895 M | -137 M | 765 M | 361 M | 1.16 B | 931 M | 1.01 B | 662 M | 749 M | 942 M | 1.11 B | 925 M | 972 M | 560 M | 801 M | -586 M | 874 M | 330 M | -60 M | 1.01 B | 928 M | 610 M | 1.04 B | 597 M | 867 M | 774 M | 1.19 B | 1.08 B | 834 M | 412 M | 753 M | 702 M | 538 M | 1.14 B | 2.4 B | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 202 M | - | - | - | 230 M | - | - | - | 201 M | - | - |
EBITDA |
853 M | -92 M | 789 M | 445 M | 1.03 B | 603 M | 664 M | 115 M | 95 M | 141 M | -66 M | 901 M | 489 M | -492 M | 152 M | -784 M | 589 M | -755 M | -513 M | 267 M | 822 M | 755 M | 676 M | 668 M | -4.09 B | 422 M | 449 M | 438 M | 174 M | -359 M | 417 M | -2.91 B | 313 M | 288 M | 1.84 B | -12.7 B | 735 M | -5.33 B | 1.38 B | -336 M | 1.34 B | 671 M | 1.47 B | 796 M | 1.32 B | 985 M | 1.08 B | 839 M | 1.47 B | 1.3 B | 1.38 B | 534 M | 1.22 B | -186 M | 1.26 B | 287 M | 352 M | 1.39 B | 1.45 B | 580 M | 1.28 B | 821 M | 1.13 B | 495 M | 1.45 B | 1.31 B | 1.07 B | 170 M | 1.01 B | 1.06 B | 592 M | 1.64 B | 2.89 B | - |
Operating Expenses |
1.73 B | 2.38 B | 1.32 B | 2.36 B | 1.42 B | 1.65 B | 1.36 B | 2.15 B | 2.2 B | 2.03 B | 1.99 B | 1.66 B | 1.51 B | 2.45 B | 1.6 B | 2.71 B | 1.24 B | 2.76 B | 2.45 B | 1.97 B | 1.17 B | 1.29 B | 1.44 B | 1.64 B | 6.19 B | 1.59 B | 1.87 B | 1.81 B | 1.91 B | 2.54 B | 1.72 B | 5.14 B | 1.96 B | 2.05 B | 790 M | 15.5 B | 2.22 B | 8.54 B | 1.88 B | 3.53 B | 2.04 B | 2.52 B | 1.63 B | 1.92 B | 1.76 B | 2.24 B | 2.09 B | 1.95 B | 1.7 B | 1.74 B | 1.72 B | 2.33 B | 1.83 B | 3.18 B | 1.72 B | 2.46 B | 2.66 B | 1.65 B | 1.68 B | 2.27 B | 1.21 B | 1.6 B | 1.32 B | 1.69 B | 1.28 B | 1.05 B | 1.18 B | 1.69 B | 1.18 B | 1.07 B | 1.03 B | - | - | - |
General and Administrative Expenses |
298 M | 317 M | 304 M | 367 M | 317 M | 305 M | 297 M | 302 M | 298 M | 283 M | 278 M | 292 M | 268 M | 307 M | 296 M | 288 M | 283 M | 313 M | 296 M | 277 M | 291 M | 242 M | 290 M | 327 M | 279 M | 264 M | 304 M | 319 M | 285 M | 296 M | 292 M | 344 M | 309 M | 316 M | 329 M | 350 M | 372 M | 363 M | 366 M | 465 M | 310 M | 311 M | 304 M | 412 M | 316 M | 325 M | 307 M | 320 M | 293 M | 302 M | 302 M | 316 M | 297 M | 319 M | 307 M | 318 M | 292 M | 316 M | 312 M | 315 M | 112 M | 284 M | 221 M | 258 M | 236 M | 189 M | 182 M | 218 M | 212 M | 197 M | 196 M | 669 M | 637 M | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Teva Pharmaceutical Industries Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Russia
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
